Pyxis Oncology Inc (PYXS) concluded trading on Wednesday at a closing price of $1.14, with 0.49 million shares of worth about $0.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -29.63% during that period and on June 18, 2025 the price saw a loss of about -4.20%. Currently the company’s common shares owned by public are about 61.63M shares, out of which, 44.02M shares are available for trading.
Stock saw a price change of -10.94% in past 5 days and over the past one month there was a price change of -7.32%. Year-to-date (YTD), PYXS shares are showing a performance of -26.92% which decreased to -69.92% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.83 but also hit the highest price of $5.39 during that period. The average intraday trading volume for Pyxis Oncology Inc shares is 475.84K. The stock is currently trading -8.14% below its 20-day simple moving average (SMA20), while that difference is up 0.38% for SMA50 and it goes to -43.33% lower than SMA200.
Pyxis Oncology Inc (NASDAQ: PYXS) currently have 61.63M outstanding shares and institutions hold larger chunk of about 37.56% of that.
The stock has a current market capitalization of $70.62M and its 3Y-monthly beta is at 1.18. It has posted earnings per share of -$1.58 in the same period. It has Quick Ratio of 7.75 while making debt-to-equity ratio of 0.19. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PYXS, volatility over the week remained 2.09% while standing at 4.04% over the month.
Stock’s fiscal year EPS is expected to drop by -4.29% while it is estimated to increase by 13.20% in next year. EPS is likely to grow at an annualized rate of 2.24% for next 5-years, compared to annual growth of -74.92% made by the stock over the past 5-years.
Coverage by Stephens stated Pyxis Oncology Inc (PYXS) stock as an Overweight in their note to investors on November 08, 2024, suggesting a price target of $13 for the stock. On August 08, 2024, Stifel Initiated their recommendations, while on May 07, 2024, Jefferies Resumed their ratings for the stock with a price target of $10. Stock get a Buy rating from BTIG Research on February 09, 2024.
